BIIB vs GILD: Side-by-Side Comparison
Compare Biogen Inc (BIIB) and Gilead Sciences Inc (GILD) side by side: market cap USD 31.91B vs USD 162.98B, P/E 23.2 vs 17.9. Financials, growth and model signals on Bullrun.
| Metric | BIIB | GILD |
|---|---|---|
| Company | Biogen Inc | Gilead Sciences Inc |
| Country / Exchange | United States · NASDAQ | United States · NASDAQ |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers-General | Drug Manufacturers-General |
| Market cap | USD 31.91B | USD 162.98B |
| P/E ratio | 23.2 | 17.9 |
| Dividend yield | — | 2.45% |
| Valuation model | 5.7% undervalued | 9.2% undervalued |
| Revenue (FY2025) | USD 9.89B | USD 29.44B |
| Revenue growth YoY | +2.2% | +2.4% |
| Net income | USD 1.29B | USD 8.51B |
| Gross margin | 75.7% | 78.8% |
| Diluted EPS | 8.79 | 6.78 |